MONTREAL, CANADA -- (MARKET WIRE) -- 04/17/07 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced the approval by Health Canada of a new one-step dosing regimen for Plan B®. Plan B® is an emergency contraceptive that prevents pregnancy from occurring when taken within 72 hours of unprotected sex. This new one-step dosing will allow women to take both pills at the same time, thereby increasing ease of use without any increase in side effects or loss of efficacy.

"This is a significant improvement for Canadian women. Plan B® is the only over-the-counter morning after pill available in Canada with this patient friendly dosing. We will be actively communicating this new and improved dosing to physicians, pharmacists and patients across Canada," said Jonathan Ross Goodman, President and CEO.

About Plan B®

Plan B® (levonorgestrel) is indicated for the prevention of pregnancy if taken within 72 hours following any unprotected act of sexual intercourse including when no contraceptive method was used, or when a contraceptive method may have failed, and in cases of sexual assault. It is comprised of two pills each containing 0.75 mg of levonorgestrel. Plan B® has been available in Canada since 2000 and has been used by over half a million women to prevent pregnancies. Since April 2005, Plan B® is available from the pharmacist without a doctor's prescription across Canada.

About Paladin Labs

Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company's web site at www.paladinlabs.com.

These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2006. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information, future events, or except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com

Contacts:
Paladin Labs Inc.
Samira Sakhia
Chief Financial Officer
514-340-5067
514-344-4675 (FAX)
info@paladin-labs.com
www.paladinlabs.com